Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q2 Revenues Climb 16 Percent, Loss Narrows

NEW YORK, July 28 (GenomeWeb News) - Luminex yesterday reported increased revenues and a narrowing loss for the second quarter of 2005.

 

Revenues for the quarter totaled $10.7 million, a 16 percent increase over last year's revenues of $9.2 million during the same quarter. Of total revenues, $4.4 million came from sales of Luminex instruments, $3.9 million from consumables, $1.2 million from royalties, and $1.1 million from other sources.

 

Research and development costs climbed to $1.5 million, up from $1 million during the year-ago quarter.

 

Luminex's net loss declined to $363,000, or $.01 per share, from $1.1 million, or $.04 per share, for last year's second quarter.

 

As of June 30, Luminex had $19.5 million in cash and cash equivalents, and $8.9 million in short-term investments.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.